Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Concert Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Concert Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Concert Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Concert Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Concert Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Concert Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Concert Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Concert Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Concert Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Concert Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Roger D. Tung, Ph.D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and major pharmaceutical companies, including Vertex Pharmaceuticals from 1989 to 2005, where he was a Founding Scientist. He also served as a Vice President of Drug Discovery for San Diego site of Vertex Pharmaceuticals from February 2002 to January 2005. He co-invented and headed discovery of Vertex's two commercial HIV protease inhibitor products, Lexiva® and Agenerase®, and led development of Agenerase® in collaboration with Glaxo through FDA and EMEA approval. He has 30 year career in the global pharmaceutical and biotechnology industries in scientific and scientific management positions at the Squibb Institute for Medical Research, Merck Research Laboratories, Concert and Vertex Pharmaceuticals. He discovered both of the marketed products of Vertex Pharmaceuticals Incorporated. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider and The Squibb Institute for Medicinal Chemistry. He is Co-Founder, President and CEO of Concert Pharmaceuticals (NASDAQ: CNCE) and BOD, Flex Pharma (NASDAQ: FLKS) He has been a Director of Concert Pharmaceuticals, Inc. since April 2006. He has been a Director of Flex Pharma, Inc. since October 31, 2017 and served as its Member of Scientific Advisory Board until October 31, 2017. He served as a Member of Scientific Advisory Board at Verastem, Inc., and Syros Pharmaceuticals, Inc. He serves as a Member of Scientific and Clinical Advisory Board at Medivation, Inc. (formerly, Orion Acquisition Corp. II.). He has published widely and been granted 47 U.S. patents. Dr. Tung received a BA in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison.
Roger's compensation has increased whilst company is loss making.
Roger's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Concert Pharmaceuticals management team is about average.
Co-Founder & Chairman of the Board
Chief Operating Officer
Chief Development Officer
Chief Financial Officer
Principal Accounting Officer & Corporate Controller
Senior Vice President of Corporate Communications and Investor Relations
Senior Legal Advisor
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Concert Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer’s disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.